Zhongzhi Pharmaceutical Holdings (3737) Fundamentals 2026 — P/E 27.0x, Revenue Analysis | SniperIQ
Zhongzhi Pharmaceutical Holdings (3737) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of HK$540M, trading at HK$0.64 on the HKSE. This SniperIQ fundamentals page covers Zhongzhi Pharmaceutical Holdings's valuation (P/E 27.0x, P/B 0.4x), profitability (net margin 1.0%), revenue (¥1.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Zhongzhi Pharmaceutical Holdings's market cap?
Zhongzhi Pharmaceutical Holdings (3737) has a market capitalization of approximately HK$540M, trading at HK$0.64 on the HKSE. Market cap moves with the live share price.
What is Zhongzhi Pharmaceutical Holdings's P/E ratio?
Zhongzhi Pharmaceutical Holdings's trailing twelve-month P/E ratio is 27.0x, with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zhongzhi Pharmaceutical Holdings?
Zhongzhi Pharmaceutical Holdings runs a net profit margin of 1.0%, a gross margin of 54.1%, and an operating margin of 0.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zhongzhi Pharmaceutical Holdings generate?
Zhongzhi Pharmaceutical Holdings reported revenue of ¥1.7B for fiscal year 2025, with net income of ¥17M and earnings per share (EPS) of 0.0205. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Zhongzhi Pharmaceutical Holdings pay a dividend?
Zhongzhi Pharmaceutical Holdings does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Zhongzhi Pharmaceutical Holdings financially healthy?
Zhongzhi Pharmaceutical Holdings carries a debt-to-equity ratio of 0.21x and a current ratio of 1.60x, with a market beta of 0.41. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zhongzhi Pharmaceutical Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zhongzhi Pharmaceutical Holdings (3737) the key facts are: market cap HK$540M, P/E 27.0x, revenue ¥1.7B, 52-week range 0.5-0.98. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Zhongzhi Pharmaceutical Holdings's full fundamentals live
Get Zhongzhi Pharmaceutical Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.